The skin cancer vaccine is based on mRNA technology that helped end the coronavirus pandemic.

Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...

Last fall, FDA safety officers began compiling a list of children possibly killed by COVID vaccines. Digging through ...

A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna ...

The data were not bad — in fact, the outcome was better than many analysts had predicted. The problem was Cambridge-based ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...

So, right now, is Moderna a buy on the dip? It's important to keep in mind that the stock still has climbed more than 500% ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

Moderna (NASDAQ: MRNA) leaped into the spotlight during the early days of the pandemic, and that was because the up-and-coming biotech player had a solution to the problem: a vacc ...

Moderna aur Merck ke shares gire jab vaccine trial data ne sirf **42%** recurrence reduction dikhaya. Investors ki badhi ...

Moderna gave investors a scare as its stock plunged on Thursday. But it's still one of the hottest biotechs this year. And it's hardly alone – the sector is on a roll and looks poised for more gains.

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial in melanoma, oncologists and the public alike were ...